Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that Tagrisso (osimertinib) has been recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating adult patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) with EGFR mutations.

The recommendation follows positive results from the LAURA Phase III trial, which demonstrated a significant improvement in progression-free survival (PFS).

In the trial, Tagrisso reduced the risk of disease progression or death by 84% compared to placebo (HR 0.16; p